Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating income | -$17.2M | -$43.2M | -$71.7M | -$114M | -$159M | -$191M |
| Net income | -$17.1M | -$42.8M | -$67.6M | -$100M | -$134M | -$168M |
| EPS (diluted) | -$23.17 | -$1.14 | -$1.26 | -$1.57 | -$1.45 | -$1.63 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$14.6M | -$33.5M | -$52.6M | -$91.9M | -$109M | -$144M |
| Capital expenditures | $203K | $668K | $5.55M | $5.75M | $1.31M | $256K |
| Free cash flow | -$14.8M | -$34.2M | -$58.2M | -$97.7M | -$110M | -$144M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $105M | $15.6M | $22.0M | $86.1M | $41.7M | $61.1M |
| Total assets | $131M | $285M | $367M | $340M | $487M | $553M |
| Total liabilities | $4.34M | $10.8M | $20.4M | $21.2M | $27.6M | $30.3M |
| Shareholders' equity | -$33.4M | $274M | $347M | $319M | $459M | $522M |
| Retained earnings | -$34.1M | -$77.0M | -$145M | -$245M | -$379M | -$546M |
| Shares (wtd avg diluted) | 739K | 37.5M | 53.6M | 63.7M | 92.4M | 103M |
Every figure is extracted from Edgewise Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.